Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status:
Completed
Trial end date:
1996-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the chemical efficacy and safety of intranasally administered peptide T on
neurocognitive function in HIV seropositive individuals.
Previous studies have shown that treatment with peptide T can result in cognitive improvement
in HIV-infected patients.
Patients are randomized to receive either peptide T or placebo for the first 6 months. All
patients then receive open-label peptide T for approximately 6 additional months.
Neuropsychologic tests are used to determine drug effects.